Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Universitat de Barcelona · Hospital Clínic de Barcelona · +31 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
3,653
total citations
- FWCI
- 162.07
- Percentile
- 100%
- References
- 35
Citations per year
Authors
24- JBJordi BruixCorresponding
Universitat de Barcelona, Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
- SQShukui Qin
81th Hospital of PLA
- PMPhilippe Merle
Hôpital Lyon Sud
- AGAlessandro Granito
Policlinico S.Orsola-Malpighi, University of Bologna
- YHYi‐Hsiang Huang
Taipei Veterans General Hospital, National Yang Ming Chiao Tung University
Topics & keywords
Topics
Keywords
- Regorafenib
- Sorafenib
- Hepatocellular carcinoma
- Placebo
- Medicine
- Double blind
- Internal medicine
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.